title: Role of sialic acid in insulin action and the insulin resistance of diabetes mellitus.
abstract: Adipocytes treated with neuraminidase show markedly reduced responsiveness to insulin without any alteration in insulin binding. In addition, several studies have separately demonstrated both insulin resistance and decreases in membrane sialic acid content and associated biosynthetic enzymes in diabetes mellitus. In the present study, we investigated the role that sialic acid residues may play in insulin action and in the hepatic insulin resistance associated with nonketotic diabetes. Primary cultures of hepatocytes from normal rats treated with neuraminidase demonstrated a dose-dependent decrease in insulin-stimulated lipogenesis. At a concentration of neuraminidase that decreases insulin action by 50%, 23% of total cellular sialic acid content was released. Neuraminidase-releasable sialic acid was significantly decreased in hepatocytes from diabetic rats and this was associated with significant insulin resistance. Treatment of hepatocytes from diabetic rats with cytidine 5'-monophospho-N-acetylneuraminic acid (CMP-NANA) enhanced insulin responsiveness 39%. The enhanced insulin responsiveness induced by CMP-NANA was blocked by cytidine 5'-monophosphate (CMP) suggesting that the CMP-NANA effect was catalyzed by a cell surface sialyltransferase. CMP reduced neuraminidase-releasable [14C]sialic acid incorporation into hepatocytes by 43%. The data demonstrate a role for cell surface sialic acid residues in hepatic insulin action and support a role for decreased cell surface sialic acid residues in the insulin resistance of diabetes mellitus.
authors.affiliation: Department of Medicine, University of Rochester Medical Center, New York 14642.
authors.forename: A I
authors.initials: AI
authors.lastname: Salhanick
authors.forename: J M
authors.initials: JM
authors.lastname: Amatruda
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D007333:Insulin Resistance; D008055:Lipids / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009439:Neuraminidase / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011972:Receptor, Insulin / Q000378:metabolism; D012016:Reference Values; D012794:Sialic Acids / Q000502:physiology*
chemical_list: D008055:Lipids; D012794:Sialic Acids; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid; D011972:Receptor, Insulin; D009439:Neuraminidase